CLINICAL TRIALS PROFILE FOR ENTEREG
✉ Email this page to a colleague
All Clinical Trials for Entereg
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00256932 ↗ | Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain | Completed | GlaxoSmithKline | Phase 3 | 2005-08-01 | Adults who are taking opioid therapy for persistent non-cancer pain and have resulting opioid-induced bowel dysfunction (OBD) will be randomized (1:1:1) to one 2 alvimopan arms, or to placebo. The primary objective of this phase 3 confirmatory study is to compare alvimopan with placebo for efficacy in the treatment of OBD. The primary efficacy endpoint is based on frequency of bowel movements. Subjects will be required to: (1) track their bowel movements and other bowel symptoms and (2) attend 6 clinic visits over 4 months. |
| NCT00256932 ↗ | Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain | Completed | Cubist Pharmaceuticals LLC | Phase 3 | 2005-08-01 | Adults who are taking opioid therapy for persistent non-cancer pain and have resulting opioid-induced bowel dysfunction (OBD) will be randomized (1:1:1) to one 2 alvimopan arms, or to placebo. The primary objective of this phase 3 confirmatory study is to compare alvimopan with placebo for efficacy in the treatment of OBD. The primary efficacy endpoint is based on frequency of bowel movements. Subjects will be required to: (1) track their bowel movements and other bowel symptoms and (2) attend 6 clinic visits over 4 months. |
| NCT00259922 ↗ | Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain | Completed | GlaxoSmithKline | Phase 3 | 2005-08-01 | Adults who are taking opioid therapy for persistent non-cancer pain and have resulting opioid-induced bowel dysfunction (OBD) will be randomized (1:1:1) to one of 2 alvimopan arms, or to placebo. The primary objective of this phase 3 confirmatory study is to compare alvimopan with placebo for efficacy in the treatment of OBD. The primary efficacy endpoint is based on frequency of bowel movements. Subjects will be required to: (1) track their bowel movements and other bowel symptoms and (2) attend 6 clinic visits over 4 months. |
| NCT00259922 ↗ | Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain | Completed | Cubist Pharmaceuticals LLC | Phase 3 | 2005-08-01 | Adults who are taking opioid therapy for persistent non-cancer pain and have resulting opioid-induced bowel dysfunction (OBD) will be randomized (1:1:1) to one of 2 alvimopan arms, or to placebo. The primary objective of this phase 3 confirmatory study is to compare alvimopan with placebo for efficacy in the treatment of OBD. The primary efficacy endpoint is based on frequency of bowel movements. Subjects will be required to: (1) track their bowel movements and other bowel symptoms and (2) attend 6 clinic visits over 4 months. |
| NCT00708201 ↗ | A Study of Alvimopan for the Management of Postoperative Ileus in Participants Undergoing Radical Cystectomy | Completed | Cubist Pharmaceuticals LLC | Phase 4 | 2009-03-01 | This study is being conducted to determine whether alvimopan can accelerate recovery of gastrointestinal function following radical cystectomy when compared with a placebo. Secondary objectives of the study are: - to evaluate the effect of alvimopan on hospital length of stay - to evaluate the effect of alvimopan on prespecified postoperative ileus (POI)-related morbidities - to evaluate the overall and cardiovascular safety of alvimopan |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Entereg
Condition Name
Clinical Trial Locations for Entereg
Trials by Country
Clinical Trial Progress for Entereg
Clinical Trial Phase
Clinical Trial Sponsors for Entereg
Sponsor Name
